Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

@article{Meyer2005RandomizedCO,
  title={Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.},
  author={R Michael Meyer and Mary Krystyna Gospodarowicz and Joseph M. Connors and Robert G Pearcey and Andrea Bezjak and Woodrow A Wells and Bruce F. Burns and Jane N. Winter and Sandra J. Horning and Abdul Rashid Dar and Marina S. Djurfeldt and Keyue Ding and Lois E. Shepherd},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 21},
  pages={
          4634-42
        }
}
  • R Michael Meyer, Mary Krystyna Gospodarowicz, +10 authors Lois E. Shepherd
  • Published in
    Journal of clinical oncology…
    2005
  • Medicine
  • PURPOSE We report results of a randomized trial comparing ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy alone with treatment that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. PATIENTS AND METHODS Patients with nonbulky clinical stage I to IIA Hodgkin's lymphoma were stratified into favorable and unfavorable risk cohorts. Patients allocated to radiation-containing therapy received subtotal nodal radiation if favorable risk or combined… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 154 CITATIONS, ESTIMATED 44% COVERAGE

    Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma

    VIEW 9 EXCERPTS
    CITES RESULTS
    HIGHLY INFLUENCED

    Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

    VIEW 9 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.

    VIEW 9 EXCERPTS
    CITES METHODS, BACKGROUND & RESULTS

    Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?

    VIEW 3 EXCERPTS
    HIGHLY INFLUENCED

    Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?

    VIEW 5 EXCERPTS
    CITES METHODS
    HIGHLY INFLUENCED

    Secondary breast cancer in Hodgkin's lymphoma survivors.

    VIEW 5 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma

    • Lale Kostakoglu
    • Medicine
    • European Journal of Nuclear Medicine and Molecular Imaging
    • 2008
    VIEW 3 EXCERPTS
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2005
    2020

    CITATION STATISTICS

    • 10 Highly Influenced Citations

    • Averaged 6 Citations per year from 2017 through 2019

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 23 REFERENCES

    Long-term cause-specific mortality of patients treated for Hodgkin's disease.

    VIEW 1 EXCERPT

    Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

    VIEW 1 EXCERPT

    Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

    VIEW 1 EXCERPT

    Two cycles ABVD plus extended field radiotherapy is ABVD for Limited-Stage Hodgkin’s Lymphoma www.jco.org 4641 Copyright © 2005 by the American Society of Clinical Oncology

    • M Sieber, J Franklin, H Tesch
    • All rights reserved
    • 2002